Stefan Dübel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1826398/publications.pdf

Version: 2024-02-01

185 papers 7,502 citations

50 h-index 77 77 g-index

307 all docs

307 docs citations

307 times ranked

7728 citing authors

#	Article	IF	CITATIONS
1	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology, 2022, 75, 13-27.	3.6	16
2	Phage Display-Derived Monoclonal Antibodies Against Internalins A and B Allow Specific Detection of Listeria monocytogenes. Frontiers in Public Health, 2022, 10, 712657.	1.3	3
3	Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant. BMC Medicine, 2022, 20, 102.	2.3	67
4	<i>In vitro</i> evolution of <i>myc-</i> tag antibodies: in-depth specificity and affinity analysis of Myc1-9E10 and Hyper-Myc. Biological Chemistry, 2022, 403, 479-494.	1.2	2
5	Investigation of Conditions for Capture of Live Legionella pneumophila with Polyclonal and Recombinant Antibodies. Biosensors, 2022, 12, 380.	2.3	1
6	ORFeome Phage Display Reveals a Major Immunogenic Epitope on the S2 Subdomain of SARS-CoV-2 Spike Protein. Viruses, 2022, 14, 1326.	1.5	4
7	Chemiegeschichte: Vom Gen zum Produkt. Nachrichten Aus Der Chemie, 2022, 70, 24-26.	0.0	O
8	Animal-versus <i>in vitro</i> -derived antibodies: avoiding the extremes. MAbs, 2021, 13, 1950265.	2.6	11
9	SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nature Communications, 2021, 12, 1577.	5.8	73
10	Plant Defense Proteins as Potential Markers for Early Detection of Forest Damage and Diseases. Frontiers in Forests and Global Change, 2021, 4, .	1.0	2
11	Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy. Frontiers in Cellular and Infection Microbiology, 2021, 11, 697876.	1.8	40
12	A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Reports, 2021, 36, 109433.	2.9	75
13	Shelf-Life Extension of Fc-Fused Single Chain Fragment Variable Antibodies by Lyophilization. Frontiers in Cellular and Infection Microbiology, 2021, 11, 717689.	1.8	7
14	Animal-free alternatives and the antibody iceberg. Nature Biotechnology, 2020, 38, 1234-1239.	9.4	58
15	Animal-derived-antibody generation faces strict reform in accordance with European Union policy on animal use. Nature Methods, 2020, 17, 755-756.	9.0	27
16	Pyruvate dehydrogenase complex—enzyme 2, a new target for Listeria spp. detection identified using combined phage display technologies. Scientific Reports, 2020, 10, 15267.	1.6	11
17	Baculovirus-free insect cell expression system for high yield antibody and antigen production. Scientific Reports, 2020, 10, 21393.	1.6	30
18	Cell-Type Targeted NF-kappaB Inhibition for the Treatment of Inflammatory Diseases. Cells, 2020, 9, 1627.	1.8	34

#	Article	IF	Citations
19	Human antibodies neutralizing diphtheria toxin in vitro and in vivo. Scientific Reports, 2020, 10, 571.	1.6	52
20	Affinity-matured variants derived from nimotuzumab keep the original fine specificity and exhibit superior biological activity. Scientific Reports, 2020, 10, 1194.	1.6	6
21	Reproducibility: bypass animals for antibody production. Nature, 2020, 581, 262-262.	13.7	17
22	Parallelized Microscale Expression of Soluble scFv. Methods in Molecular Biology, 2019, 2025, 203-211.	0.4	1
23	Cytosolic Delivery of Macromolecules in Live Human Cells Using the Combined Endosomal Escape Activities of a Small Molecule and Cell Penetrating Peptides. ACS Chemical Biology, 2019, 14, 2641-2651.	1.6	38
24	Rekombinante Antikörper., 2019,,.		1
25	Directed evolution of super-secreted variants from phage-displayed human Interleukin-2. Scientific Reports, 2019, 9, 800.	1.6	14
26	Modeling Neurodegenerative Spinocerebellar Ataxia Type 13 in Zebrafish Using a Purkinje Neuron Specific Tunable Coexpression System. Journal of Neuroscience, 2019, 39, 3948-3969.	1.7	31
27	Radiometal-labeled anti-VCAM-1 nanobodies as molecular tracers for atherosclerosis – impact of radiochemistry on pharmacokinetics. Biological Chemistry, 2019, 400, 323-332.	1.2	19
28	Human Anti-Lipopolysaccharid (LPS) antibodies against Legionella with high species specificity. Human Antibodies, 2019, 26, 29-38.	0.6	10
29	When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions. MAbs, 2018, 10, 539-546.	2.6	74
30	Trendbericht Biochemie 2017: Menschliche Antik \tilde{A} rper f \tilde{A} 1/4r Medikamente. Nachrichten Aus Der Chemie, 2018, 66, 284-290.	0.0	1
31	Sequence defined antibodies improve the detection of cadherin 2 (N-cadherin) during zebrafish development. New Biotechnology, 2018, 45, 98-112.	2.4	12
32	The sneaking ligand approach for cell type-specific modulation of intracellular signalling pathways. Clinical Immunology, 2018, 186, 14-20.	1.4	3
33	ORFeome Phage Display. Methods in Molecular Biology, 2018, 1701, 477-495.	0.4	8
34	Development of Neutralizing and Non-neutralizing Antibodies Targeting Known and Novel Epitopes of TcdB of Clostridioides difficile. Frontiers in Microbiology, 2018, 9, 2908.	1.5	18
35	Viele monoklonale Antikörper sind nicht monospezifisch. BioSpektrum, 2018, 24, 395-399.	0.0	0
36	Structural insights into antigen recognition of an anti- \hat{l}^2 -(1,6)- \hat{l}^2 -(1,3)-D-glucan antibody. Scientific Reports, 2018, 8, 13652.	1.6	7

#	Article	IF	Citations
37	Culture and Transfection of Zebrafish Primary Cells. Journal of Visualized Experiments, 2018, , .	0.2	2
38	Antibody fusion proteins with human ribonucleases 1 to 8. Human Antibodies, 2018, 26, 177-192.	0.6	3
39	A strategy to identify linker-based modules for the allosteric regulation of antibody-antigen binding affinities of different scFvs. MAbs, 2017, 9, 404-418.	2.6	14
40	Single amino acid fingerprinting of the human antibody repertoire with high density peptide arrays. Journal of Immunological Methods, 2017, 443, 45-54.	0.6	45
41	Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV. MAbs, 2017, 9, 831-843.	2.6	19
42	Designing Human Antibodies by Phage Display. Transfusion Medicine and Hemotherapy, 2017, 44, 312-318.	0.7	78
43	Embryonic zebrafish primary cell culture for transfection and live cellular and subcellular imaging. Developmental Biology, 2017, 430, 18-31.	0.9	13
44	Evaluating the Delivery of Proteins to the Cytosol of Mammalian Cells. Methods in Molecular Biology, 2017, 1513, 201-208.	0.4	7
45	Generation of Recombinant Antibodies against the beta-(1,6)-Branched beta-(1,3)-D-Glucan Schizophyllan from Immunized Mice via Phage Display. Biotechnology Research International, 2017, 2017, 1-8.	1.4	5
46	Low-cost, in-liquid measuring system using a novel compact oscillation circuit and quartz-crystal microbalancesÂ(QCMs) as a versatile biosensor platform. Journal of Sensors and Sensor Systems, 2017, 6, 341-350.	0.6	15
47	Recent Advances with ER Targeted Intrabodies. Advances in Experimental Medicine and Biology, 2016, 917, 77-93.	0.8	11
48	Single Chain Antibodies as Tools to Study transforming growth factor- \hat{I}^2 -Regulated SMAD Proteins in Proximity Ligation-Based Pharmacological Screens. Molecular and Cellular Proteomics, 2016, 15, 1848-1856.	2.5	10
49	Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?. Computational and Structural Biotechnology Journal, 2016, 14, 304-308.	1.9	54
50	Mining gut microbiome oligopeptides by functional metaproteome display. Scientific Reports, 2016, 6, 34337.	1.6	19
51	Utilisation of antibody microarrays for the selection of specific and informative antibodies from recombinant library binders of unknown quality. New Biotechnology, 2016, 33, 574-581.	2.4	10
52	The INNs and outs of antibody nonproprietary names. MAbs, 2016, 8, 1-9.	2.6	48
53	Recent Advances with ER Targeted Intrabodies. , 2015, , 77-93.		0
54	Generation and analysis of the improved human HAL9/10 antibody phage display libraries. BMC Biotechnology, 2015, 15, 10.	1.7	115

#	Article	IF	Citations
55	The Translocon Protein Sec61 Mediates Antigen Transport from Endosomes in the Cytosol for Cross-Presentation to CD8+ T Cells. Immunity, 2015, 42, 850-863.	6.6	136
56	Structural differences of amyloid- \hat{l}^2 fibrils revealed by antibodies from phage display. BMC Biotechnology, 2015, 15, 57.	1.7	12
57	Specific <i>in vivo</i> knockdown of protein function by intrabodies. MAbs, 2015, 7, 1010-1035.	2.6	89
58	The "Sneaking-Ligand―Approach: Cell-Type Specific Inhibition of the Classical NF-κB Pathway. Methods in Molecular Biology, 2015, 1280, 559-578.	0.4	5
59	Delivery of antibodies to the cytosol. MAbs, 2014, 6, 943-956.	2.6	67
60	Functional knock down of VCAM1 in mice mediated by endoplasmatic reticulum retained intrabodies. MAbs, 2014, 6, 1394-1401.	2.6	22
61	The influence of antibody fragment format on phage display based affinity maturation of IgG. MAbs, 2014, 6, 204-218.	2.6	84
62	Human-like antibodies neutralizing Western equine encephalitis virus. MAbs, 2014, 6, 717-726.	2.6	27
63	Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform. MAbs, 2014, 6, 367-380.	2.6	9
64	Selection of Recombinant Antibodies from Antibody Gene Libraries. Methods in Molecular Biology, 2014, 1101, 305-320.	0.4	13
65	Cellâ€free eukaryotic systems for the production, engineering, and modification of scFv antibody fragments. Engineering in Life Sciences, 2014, 14, 387-398.	2.0	41
66	Patent Issues Relating to Therapeutic Antibodies. , 2014, , 705-734.		0
67	Monoclonal Antibody Nomenclature for Clinical Studies (USA)1., 2014, , 1283-1288.		0
68	Identification of Immunogenic Antigens from <i>Aspergillus fumigatus</i> by Direct Multiparameter Characterization of Specific Conventional and Regulatory CD4+ T Cells. Journal of Immunology, 2014, 193, 3332-3343.	0.4	58
69	Novel human recombinant antibodies against Mycobacterium tuberculosis antigen 85B. BMC Biotechnology, 2014, 14, 68.	1.7	20
70	Production of single chain fragment variable (scFv) antibodies in Escherichia coli using the LEXâ,,¢ bioreactor. Journal of Biotechnology, 2013, 163, 105-111.	1.9	23
71	Identification of a new epitope for HIVâ€neutralizing antibodies in the gp41 membrane proximal external region by an Envâ€tailored phage display library. European Journal of Immunology, 2013, 43, 499-509.	1.6	16
72	NF- \hat{l}° B inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF- \hat{l}° B in immune-mediated diseases. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16556-16561.	3.3	77

#	Article	IF	Citations
73	Recombinant antibody fragments allow repeated measurements of C-reactive protein with a quartz crystal microbalance immunosensor. MAbs, 2013, 5, 140-149.	2.6	8
74	Identification of immunogenic proteins and generation of antibodies against Salmonella Typhimurium using phage display. BMC Biotechnology, 2012, 12, 29.	1.7	31
75	Construction of Human Naive Antibody Gene Libraries. Methods in Molecular Biology, 2012, 907, 85-107.	0.4	20
76	Isolation and Characterisation of a Human-Like Antibody Fragment (scFv) That Inactivates VEEV In Vitro and In Vivo. PLoS ONE, 2012, 7, e37242.	1.1	41
77	Human antibodies targeting CD30+ lymphomas. Human Antibodies, 2012, 21, 13-28.	0.6	10
78	Recombinant Antibodies and In Vitro Selection Technologies. Methods in Molecular Biology, 2012, 901, 11-32.	0.4	59
79	Suppression of p75 Neurotrophin Receptor Surface Expression with Intrabodies Influences Bcl-xL mRNA Expression and Neurite Outgrowth in PC12 Cells. PLoS ONE, 2012, 7, e30684.	1.1	25
80	Development of Human and Macaque Antibodies Using Antibody Phage Display for the Detection of Equine Encephalitis Viruses. , $2011, \dots$		0
81	Beyond natural antibodies: the power of in vitro display technologies. Nature Biotechnology, 2011, 29, 245-254.	9.4	482
82	Isolation of scFv fragments specific to OmpD of Salmonella Typhimurium. Veterinary Microbiology, 2011, 147, 162-169.	0.8	28
83	Antibody production in <i>Bacillus megaterium</i> : Strategies and physiological implications of scaling from microtiter plates to industrial bioreactors. Biotechnology Journal, 2011, 6, 1516-1531.	1.8	20
84	Influence of the hydromechanical stress and temperature on growth and antibody fragment production with Bacillus megaterium. Applied Microbiology and Biotechnology, 2011, 91, 81-90.	1.7	14
85	Efficient production of soluble recombinant single chain Fv fragments by a Pseudomonas putida strain KT2440 cell factory. Microbial Cell Factories, 2011, 10, 11.	1.9	45
86	A human scFv antibody generation pipeline for proteome research. Journal of Biotechnology, 2011, 152, 159-170.	1.9	127
87	Targeting antibodies to the cytoplasm. MAbs, 2011, 3, 3-16.	2.6	93
88	Rise and Fall of an Anti-MUC1 Specific Antibody. PLoS ONE, 2011, 6, e15921.	1.1	73
89	Using the power of in vitro selection by phage display to identify recombinant antibodies with optimised properties to various life threatening viruses. Journal of Antivirals & Antiretrovirals, 2011, 02, .	0.1	0
90	Oligomeric forms of single chain immunoglobulin (sclgG). MAbs, 2010, 2, 73-76.	2.6	15

#	Article	IF	CITATIONS
91	Cloning of Variable Domains from Mouse Hybridoma by PCR. , 2010, , 3-14.		5
92	Towards proteome scale antibody selections using phage display. New Biotechnology, 2010, 27, 118-128.	2.4	53
93	Generating recombinant antibodies to the complete human proteome. Trends in Biotechnology, 2010, 28, 333-339.	4.9	98
94	Phage display-based identification and potential diagnostic application of novel antigens from Mycoplasma mycoides subsp. mycoides small colony type. Veterinary Microbiology, 2010, 142, 285-292.	0.8	22
95	V-gene amplification revisited – An optimised procedure for amplification of rearranged human antibody genes of different isotypes. New Biotechnology, 2010, 27, 108-117.	2.4	29
96	Minimum information about a protein affinity reagent (MIAPAR). Nature Biotechnology, 2010, 28, 650-653.	9.4	50
97	A Community Standard Format for the Representation of Protein Affinity Reagents. Molecular and Cellular Proteomics, 2010, 9, 1-10.	2.5	35
98	Human Antibody Gene Libraries. , 2010, , 65-84.		5
99	Improving Phage Display Throughput by Using Hyperphage, Miniaturized Titration and pVIII (g8p) ELISA. , 2010, , 197-206.		2
100	Production of Recombinant Human IgG Antibodies in the Baculovirus Expression System. , 2010, , 453-470.		2
101	Affinity Maturation by Phage Display. Methods in Molecular Biology, 2009, 525, 309-322.	0.4	46
102	Targeted therapeutic RNases (ImmunoRNases). Expert Opinion on Biological Therapy, 2009, 9, 79-95.	1.4	56
103	Functional knockdown of VCAM-1 at the posttranslational level with ER retained antibodies. Journal of Immunological Methods, 2009, 341, 30-40.	0.6	22
104	A multi-Fc-species system for recombinant antibody production. BMC Biotechnology, 2009, 9, 14.	1.7	45
105	Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnology, 2009, 9, 60.	1.7	82
106	Improved microtitre plate production of single chain Fv fragments in Escherichia coli. New Biotechnology, 2009, 25, 424-428.	2.4	43
107	Identification of a Putative Crf Splice Variant and Generation of Recombinant Antibodies for the Specific Detection of Aspergillus fumigatus. PLoS ONE, 2009, 4, e6625.	1.1	63
108	SRP and Sec pathway leader peptides for antibody phage display and antibody fragment production in E. coli. New Biotechnology, 2008, 25, 49-54.	2.4	53

#	Article	IF	CITATIONS
109	Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnology, 2008, 8, 66.	1.7	73
110	Production systems for recombinant antibodies. Frontiers in Bioscience - Landmark, 2008, Volume, 4576.	3.0	75
111	Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood, 2008, 111, 3830-3837.	0.6	72
112	Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy. Current Pharmaceutical Biotechnology, 2008, 9, 231-234.	0.9	14
113	Phage Display Derived Therapeutic Antibodies. Current Pharmaceutical Biotechnology, 2008, 9, 439-446.	0.9	84
114	High-Affinity, Human Antibody-Like Antibody Fragment (Single-Chain Variable Fragment) Neutralizing the Lethal Factor (LF) of Bacillus anthracis by Inhibiting Protective Antigen-LF Complex Formation. Antimicrobial Agents and Chemotherapy, 2007, 51, 2758-2764.	1.4	105
115	New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicityin vivo. Leukemia and Lymphoma, 2007, 48, 1179-1186.	0.6	27
116	Analysis of IgG heavy chain to light chain ratio with mutant Encephalomyocarditis virus internal ribosome entry site. Protein Engineering, Design and Selection, 2007, 20, 491-496.	1.0	47
117	Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer. International Journal of Oncology, 2007, 31, 951.	1.4	8
118	On the influence of vector design on antibody phage display. Journal of Biotechnology, 2007, 127, 626-637.	1.9	90
119	Selection of Recombinant Antibodies From Antibody Gene Libraries. Methods in Molecular Biology, 2007, 408, 243-255.	0.4	30
120	Production of recombinant antibody fragments in Bacillus megaterium. Microbial Cell Factories, 2007, 6, 2.	1.9	44
121	Production of single chain Fab (scFab) fragments in Bacillus megaterium. Microbial Cell Factories, 2007, 6, 38.	1.9	26
122	Single chain Fab (scFab) fragment. BMC Biotechnology, 2007, 7, 14.	1.7	113
123	ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nature Methods, 2007, 4, 13-17.	9.0	231
124	A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies. Journal of Immunological Methods, 2007, 318, 113-124.	0.6	110
125	Recombinant therapeutic antibodies. Applied Microbiology and Biotechnology, 2007, 74, 723-729.	1.7	60
126	Enrichment of open reading frames presented on bacteriophage M13 using Hyperphage. BioTechniques, 2006, 41, 335-342.	0.8	45

#	Article	IF	Citations
127	Measuring Biomolecular Binding Events with a Compact Disc Player Device. Angewandte Chemie - International Edition, 2006, 45, 270-273.	7.2	56
128	Analysis of Protein Interactions with Immobilized Peptide Arrays Synthesized on Membrane Supports. Cold Spring Harbor Protocols, 2006, 2006, pdb.prot4566-pdb.prot4566.	0.2	10
129	A single chain antibody obtained by cell panning of antibody phage inhibits homoaggregation of human leukemia cells. Human Antibodies, 2005, 13, 111-118.	0.6	O
130	Parameters affecting the display of antibodies on phage. Journal of Immunological Methods, 2005, 301, 173-185.	0.6	54
131	Screening of Molecular Repertoires by Microbial Surface Display. Combinatorial Chemistry and High Throughput Screening, 2005, 8, 127-133.	0.6	23
132	Perspectives for systematic in vitro antibody generation. Gene, 2005, 364, 19-29.	1.0	71
133	Phage Display Vectors for the In Vitro Generation of Human Antibody Fragments., 2005, 295, 71-96.		38
134	Cloning Single-Chain Antibody Fragments (scFv) from Hybridoma Cells., 2004, 94, 447-458.		23
135	Mating antibody phage display with proteomics. Trends in Biotechnology, 2004, 22, 8-14.	4.9	134
136	Rekombinante Antikörper: Werkzeuge gegen Krebs, Infektionen und Autoimmunerkrankungen?. Biologie in Unserer Zeit, 2004, 34, 372-379.	0.3	3
137	Hyperphage: Improving Antibody Presentation in Phage Display. , 2003, 205, 295-302.		10
138	cTAGE: A Cutaneous T Cell Lymphoma Associated Antigen Family with Tumor-Specific Splicing. Journal of Investigative Dermatology, 2003, 121, 198-206.	0.3	52
139	The Rapeutic Antibodies and Antibody Fusion Proteins. Biotechnology and Genetic Engineering Reviews, 2003, 20, 137-164.	2.4	14
140	Mutations in the N-Terminus of the Major Coat Protein (pVIII, gp8) of Filamentous Bacteriophage Affect Infectivity. Journal of Molecular Microbiology and Biotechnology, 2003, 6, 57-66.	1.0	14
141	A helper phage to improve single-chain antibody presentation in phage display. Nature Biotechnology, 2001, 19, 75-78.	9.4	265
142	Baculovirus expression cassette vectors for rapid production of complete human IgG from phage display selected antibody fragments. Journal of Immunological Methods, 2001, 247, 119-130.	0.6	59
143	Functional Characterization of Recombinant Chloroplast Signal Recognition Particle. Journal of Biological Chemistry, 2001, 276, 27778-27786.	1.6	70
144	Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design. Journal of Immunology, 2001, 166, 5271-5278.	0.4	73

#	Article	IF	CITATIONS
145	Recombinant Antibodies., 2001,, 3-16.		2
146	Construction of scFv from Hybridoma by Two-Step Cloning. , 2001, , 41-55.		5
147	Generation of Antibody Gene Libraries from Seropositive Human Donors., 2001,, 109-123.		3
148	Production of Recombinant Human IgG Antibodies in the Baculovirus Expression System. , 2001 , , $334-356$.		0
149	Affinity Measurements of Antibody Fragments on Phage by Quartz Crystal Microbalance (QCM)., 2001,, 397-406.		1
150	Functional Minipreps of scFv-Antibody Fragments. , 2001, , 257-265.		0
151	The antibody web. Trends in Immunology, 2000, 21, 355-357.	7.5	5
152	Effects of unpaired cysteines on yield, solubility and activity of different recombinant antibody constructs expressed in E. coli. Journal of Immunological Methods, 2000, 242, 101-114.	0.6	72
153	Rapid Titration of Multiple Samples of Filamentous Bacteriophage (M13) on Nitrocellulose Filters. BioTechniques, 2000, 29, 1196-1202.	0.8	14
154	Expression of a bispecific dsFvâ€⁴ dsFv′ antibody fragment in Escherichia coli. Protein Engineering, Design and Selection, 2000, 13, 725-734.	1.0	38
155	Protein stabilization through phage display. FEBS Letters, 2000, 476, 296-300.	1.3	9
156	Primary structure of the antigen-binding domains of a human oligodendrocyte-reactive IgM monoclonal antibody derived from a patient with multiple sclerosis. Journal of Neuroimmunology, 1999, 99, 122-130.	1.1	7
157	Fine mapping of the antigen-antibody interaction of scFv215, a recombinant antibody inhibiting RNA polymerase II fromDrosophila melanogaster., 1999, 12, 103-111.		15
158	Epitope structures recognised by antibodies against the major coat protein (g8p) of filamentous bacteriophage fd (Inoviridae). Journal of Molecular Biology, 1999, 288, 21-28.	2.0	34
159	Recent Developments in Antibody Engineering. , 1998, 13, 555-580.		0
160	Cloning and Expression of Single-Chain Fragments (SCFV) from Mouse and Rat Hybridomas. , 1998, 13, 581-592.		4
161	Primary Structure and Functional Expression of Heavy- and Light-Chain Variable Region Genes of a Monoclonal Antibody Specific for Human Fibrin. Hybridoma, 1997, 16, 235-241.	0.9	4
162	Primary Structure and Functional scFv Antibody Expression of an Antibody Against the Human Protooncogen c-myc. Hybridoma, 1997, 16, 227-233.	0.9	13

#	Article	IF	CITATIONS
163	Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnology: an International Journal of Immunological Engineering, 1997, 3, 127-136.	2.4	60
164	Separation of E. coli expressing functional cell-wall bound antibody fragments by FACS. Immunotechnology: an International Journal of Immunological Engineering, 1996, 2, 97-102.	2.4	32
165	Molecular Cloning of Tissue-Specific Transcripts of a Transketolase-Related Gene: Implications for the Evolution of New Vertebrate Genes. Genomics, 1996, 32, 309-316.	1.3	96
166	Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment–core streptavidin fusion. Protein Engineering, Design and Selection, 1996, 9, 203-211.	1.0	82
167	Single-chain antibody streptavidin fusions: Tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen. Human Antibodies, 1995, 6, 93-101.	0.6	28
168	Bacterial expression and refolding of single-chain Fv fragments with C-terminal cysteines. Cell Biophysics, 1995, 26, 187-204.	0.4	32
169	Characterization of the Epitope Recognized by a Monoclonal Antibody Directed against the Largest Subunit ofDrosophilaRNA Polymerase II. Biological Chemistry Hoppe-Seyler, 1995, 376, 473-482.	1.4	31
170	Human antibody libraries in Escherichia coli. Journal of Biotechnology, 1995, 41, 187-195.	1.9	19
171	Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers. Journal of Immunological Methods, 1994, 175, 89-95.	0.6	56
172	Surface display of antibodies. Biotechnology Advances, 1994, 12, 539-555.	6.0	21
173	Recombinant single-chain Fv fragments carrying C-terminal cysteine residues: Production of bivalent and biotinylated miniantibodies. Molecular Immunology, 1994, 31, 1047-1058.	1.0	84
174	A vector for the removal of deletion mutants from antibody libraries. Gene, 1992, 114, 235-237.	1.0	34
175	Targeting Recombinant Antibodies to the Surface of Escherichia coli: Fusion to a Peptidoglycan Associated Lipoprotein. Bio/technology, 1991, 9, 1369-1372.	1.9	115
176	A surface expression vector for antibody screening. Gene, 1991, 104, 147-153.	1.0	312
177	Terminal differentiation of head- and foot-specific epithelial cells occurs at the same location in hydra tissue without polarity. Developmental Biology, 1990, 138, 243-245.	0.9	8
178	Cell differentiation in the head of Hydra. Differentiation, 1989, 41, 99-109.	1.0	29
179	Differentiation pathways of ectodermal epithelial cells in hydra. Differentiation, 1987, 35, 181-189.	1.0	70
180	Emerging Technologies for Antibody Selection., 0,, 431-443.		0

#	Article	IF	CITATIONS
181	Natalizumab (Tysabri). , 0, , 941-950.		O
182	Therapeutic Antibodies - From Past to Future. , 0, , 2-16.		1
183	Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Ibritumomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab, and Votumumab. , 0, , 1131-1147.		O
184	Intellectual Property Issues. , 0, , 301-322.		2
185	Pharmaceutical Formulation and Clinical Application. , 0, , 239-265.		0